miR‑448 promotes progression of non‑small‑cell lung cancer via targeting SIRT1

  • Authors:
    • Hongfeng Qi
    • Haifeng Wang
    • Dabin Pang
  • View Affiliations

  • Published online on: July 5, 2019     https://doi.org/10.3892/etm.2019.7738
  • Pages: 1907-1913
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Deregulation of microRNAs (miRs) has been demonstrated to be involved in both the initiation and the development of non‑small‑cell lung cancer (NSCLC). miR‑448 has been identified as a tumor suppressor in several cancer types. The aim of the present study was to explore the role of miR‑448 in NSCLC. Tumor tissues and paired normal tissues were obtained from patients with NSCLC. The viability and migration of A549 cells were determined by the Cell Counting kit‑8 and wound‑healing assays, respectively. Gene and protein levels were detected by reverse transcription‑quantitative polymerase chain reaction analysis and western blotting, respectively. The interaction between the 3' untranslated region of sirtuin1 (SIRT1) and miR‑448 was predicted by TargetScan and verified by dual luciferase reporter assay. miR‑448 levels were revealed to be decreased whereas SIRT1 levels were increased in NSCLC tissues compared with normal tissues. Pearson's correlation analysis demonstrated that there was a negative correlation between miR‑448 and SIRT1 mRNA levels. Overexpression of miR‑448 led to reduced growth and migration ability of A549 cells. In addition, overexpression of miR‑448 decreased SIRT1 mRNA and protein levels, thereby inhibiting epithelial‑mesenchymal transition (EMT) and affecting EMT‑associated molecules, including vimentin and E‑cadherin. Dual luciferase reporter assay confirmed that SIRT1 was a direct target of miR‑448. Notably, activation of SIRT1 by resveratrol treatment partially reversed the cell growth inhibition induced by miR‑448 mimics. These findings suggested that the progression of NSCLC may be controlled by miR‑448, which appears to hold promise as a therapeutic target for patients with NSCLC.

References

1 

Torre LA, Siegel RL and Jemal A: Lung cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI

2 

Niklinski J, Niklinska W, Chyczewski L, Becker HD and Pluygers E: Molecular genetic abnormalities in premalignant lung lesions: Biological and clinical implications. Eur J Cancer Prev. 10:213–226. 2001. View Article : Google Scholar : PubMed/NCBI

3 

Zhou J, Song XB, He H, Zhou Y, Lu XJ and Ying BW: Prevalence and clinical profile of EGFR mutation in non-small-cell lung carcinoma patients in Southwest China. Asian Pac J Cancer Prev. 17:965–971. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Wu S, Zhao X, Wu S, Du R, Zhu Q, Fang H, Zhang X, Zhang C, Zheng W, Yang J and Feng H: Overexpression of B7-H3 correlates with aggressive clinicopathological characteristics in non-small cell lung cancer. Oncotarget. 7:81750–81756. 2016. View Article : Google Scholar : PubMed/NCBI

5 

Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI

6 

Mendell JT: MicroRNAs: Critical regulators of development, cellular physiology and malignancy. Cell Cycle. 4:1179–1184. 2005. View Article : Google Scholar : PubMed/NCBI

7 

Iorio MV and Croce CM: MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol. 27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI

8 

Liu T, Wu X, Chen T, Luo Z and Hu X: Downregulation of DNMT3A by miR-708-5p inhibits lung cancer stem cell-like phenotypes through repressing wnt/β-catenin signaling. Clin Cancer Res. 24:1748–1760. 2018. View Article : Google Scholar : PubMed/NCBI

9 

Pang W, Tian X, Bai F, Han R, Wang J, Shen H, Zhang X, Liu Y, Yan X, Jiang F and Xing L: Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer. Mol Cancer. 13:2402014. View Article : Google Scholar : PubMed/NCBI

10 

Paliouras AR, Monteverde T and Garofalo M: Oncogene-induced regulation of microRNA expression: Implications for cancer initiation, progression and therapy. Cancer Lett. 421:152–160. 2018. View Article : Google Scholar : PubMed/NCBI

11 

Fadejeva I, Olschewski H and Hrzenjak A: MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas. Oncotarget. 8:115754–115773. 2017. View Article : Google Scholar : PubMed/NCBI

12 

Li S, Gao M, Li Z, Song L, Gao X, Han J, Wang F, Chen Y, Li W, Yang J and Han X: Role of microRNAs in metastasis of non-small cell lung cancer. Front Biosci (Landmark Ed). 21:998–1005. 2016. View Article : Google Scholar : PubMed/NCBI

13 

Zhou Q, Huang SX, Zhang F, Li SJ, Liu C, Xi YY, Wang L, Wang X, He QQ, Sun CC and Li DJ: MicroRNAs: A novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer. Cell Prolif. 50:123942017. View Article : Google Scholar

14 

Li QQ, Chen ZQ, Cao XX, Xu JD, Xu JW, Chen YY, Wang WJ, Chen Q, Tang F, Liu XP and Xu ZD: Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells. Cell Death Differ. 18:16–25. 2011. View Article : Google Scholar : PubMed/NCBI

15 

Zhu H, Zhou X, Ma C, Chang H, Li H, Liu F and Lu J: Low expression of miR-448 induces EMT and promotes invasion by regulating ROCK2 in hepatocellular carcinoma. Cell Physiol Biochem. 36:487–498. 2015. View Article : Google Scholar : PubMed/NCBI

16 

Li B, Ge L, Li M, Wang L and Li Z: miR-448 suppresses proliferation and invasion by regulating IGF1R in colorectal cancer cells. Am J Transl Res. 8:3013–3022. 2016.PubMed/NCBI

17 

Shan C, Fei F, Li F, Zhuang B, Zheng Y, Wan Y and Chen J: miR-448 is a novel prognostic factor of lung squamous cell carcinoma and regulates cells growth and metastasis by targeting DCLK1. Biomed Pharmacother. 89:1227–1234. 2017. View Article : Google Scholar : PubMed/NCBI

18 

Bordone L and Guarente L: Calorie restriction, SIRT1 and metabolism: Understanding longevity. Nat Rev Mol Cell Biol. 6:298–305. 2005. View Article : Google Scholar : PubMed/NCBI

19 

Ong ALC and Ramasamy TS: Role of Sirtuin1-p53 regulatory axis in aging, cancer and cellular reprogramming. Ageing Res Rev. 43:64–80. 2018. View Article : Google Scholar : PubMed/NCBI

20 

Liu T, Liu PY and Marshall GM: The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 69:1702–1705. 2009. View Article : Google Scholar : PubMed/NCBI

21 

Li Y, Xu S, Li J, Zheng L, Feng M, Wang X, Han K, Pi H, Li M, Huang X, et al: SIRT1 facilitates hepatocellular carcinoma metastasis by promoting PGC-1α-mediated mitochondrial biogenesis. Oncotarget. 7:29255–29274. 2016.PubMed/NCBI

22 

Zou Q, Tang Q, Pan Y, Wang X, Dong X, Liang Z and Huang D: MicroRNA-22 inhibits cell growth and metastasis in breast cancer via targeting of SIRT1. Exp Ther Med. 14:1009–1016. 2017. View Article : Google Scholar : PubMed/NCBI

23 

Chen Y, Wang T, Wang W, Hu J, Li R, He S and Yang J: Prognostic and clinicopathological significance of SIRT1 expression in NSCLC: A meta-analysis. Oncotarget. 8:62537–62544. 2017.PubMed/NCBI

24 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

25 

Ye Z, Fang B, Pan J, Zhang N, Huang J, Xie C, Lou T and Cao Z: miR-138 suppresses the proliferation, metastasis and autophagy of non-small cell lung cancer by targeting Sirt1. Oncol Rep. 37:3244–3252. 2017. View Article : Google Scholar : PubMed/NCBI

26 

Liu X, Shao K and Sun T: SIRT1 regulates the human alveolar epithelial A549 cell apoptosis induced by pseudomonas aeruginosa lipopolysaccharide. Cell Physiol Biochem. 31:92–101. 2013. View Article : Google Scholar : PubMed/NCBI

27 

Powrozek T, Krawczyk P, Kowalski DM, Kuźnar-Kamińska B, Winiarczyk K, Olszyna-Serementa M, Batura-Gabryel H and Milanowski J: Application of plasma circulating microRNA-448, 506, 4316, and 4478 analysis for non-invasive diagnosis of lung cancer. Tumour Biol. 37:2049–2055. 2016. View Article : Google Scholar : PubMed/NCBI

28 

Guan Y, Rao Z and Chen C: miR-30a suppresses lung cancer progression by targeting SIRT1. Oncotarget. 9:4924–4934. 2017.PubMed/NCBI

29 

Li T, Ma J, Han X, Jia Y, Yuan H, Shui S and Guo D: MicroRNA-320 enhances radiosensitivity of glioma through down-regulation of sirtuin type 1 by directly targeting forkhead box protein M1. Transl Oncol. 11:205–212. 2018. View Article : Google Scholar : PubMed/NCBI

30 

Wang Y, Wang DS, Cheng YS, Jia BL, Yu G, Yin XQ and Wang Y: Expression of MicroRNA-448 and SIRT1 and prognosis of obese type 2 diabetic mellitus patients after laparoscopic bariatric surgery. Cell Physiol Biochem. 45:935–950. 2018. View Article : Google Scholar : PubMed/NCBI

31 

Wu X, Yan L, Liu Y, Xian W, Wang L and Ding X: MicroRNA-448 suppresses osteosarcoma cell proliferation and invasion through targeting EPHA7. PLoS One. 12:e01755532017. View Article : Google Scholar : PubMed/NCBI

32 

Sun T, Jiao L, Wang Y, Yu Y and Ming L: SIRT1 induces epithelial-mesenchymal transition by promoting autophagic degradation of E-cadherin in melanoma cells. Cell Death Dis. 9:1362018. View Article : Google Scholar : PubMed/NCBI

33 

Ray U, Roy SS and Chowdhury SR: Lysophosphatidic acid promotes epithelial to mesenchymal transition in ovarian cancer cells by repressing SIRT1. Cell Physiol Biochem. 41:795–805. 2017. View Article : Google Scholar : PubMed/NCBI

34 

Ma P, Ni K, Ke J, Zhang W, Feng Y and Mao Q: miR-448 inhibits the epithelial-mesenchymal transition in breast cancer cells by directly targeting the E-cadherin repressor ZEB1/2. Exp Biol Med (Maywood). 243:473–480. 2018. View Article : Google Scholar : PubMed/NCBI

35 

Yang J and Weinberg RA: Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Qi, H., Wang, H., & Pang, D. (2019). miR‑448 promotes progression of non‑small‑cell lung cancer via targeting SIRT1. Experimental and Therapeutic Medicine, 18, 1907-1913. https://doi.org/10.3892/etm.2019.7738
MLA
Qi, H., Wang, H., Pang, D."miR‑448 promotes progression of non‑small‑cell lung cancer via targeting SIRT1". Experimental and Therapeutic Medicine 18.3 (2019): 1907-1913.
Chicago
Qi, H., Wang, H., Pang, D."miR‑448 promotes progression of non‑small‑cell lung cancer via targeting SIRT1". Experimental and Therapeutic Medicine 18, no. 3 (2019): 1907-1913. https://doi.org/10.3892/etm.2019.7738